How Cosentyx Works and Its Impact on Vaccines
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A), a cytokine driving inflammation in autoimmune conditions like psoriasis, psoriatic arthritis, and ankylosing spondylitis. By binding and neutralizing IL-17A, it suppresses immune responses mediated by Th17 cells, which are key for fighting certain infections.[1]
Live vaccines contain weakened but replication-competent pathogens (e.g., measles-mumps-rubella, varicella, oral polio). They rely on the patient's immune system to mount a full response, including innate and adaptive immunity involving IL-17 pathways, to build protective antibodies and memory cells.
Why It Interferes Specifically with Live Vaccines
Cosentyx dampens this process by inhibiting IL-17A, which impairs the recruitment of neutrophils and other effectors needed for viral clearance and vaccine-induced immunity. Clinical data show reduced antibody responses to live vaccines during treatment—patients on Cosentyx produce lower titers against measles and varicella antigens compared to placebo.[2] This happens because:
- IL-17A supports mucosal immunity and T-cell activation at infection sites, both critical for live vaccine replication and antigen presentation.
- The drug's half-life (about 27 days) means suppression persists for months, overlapping with peak vaccine response windows (2-4 weeks post-vaccination).[3]
Inactivated or subunit vaccines (e.g., flu shot, HPV) don't replicate, so they bypass IL-17-dependent steps and remain effective.
Timing and Recommendations for Patients
Avoid live vaccines during Cosentyx treatment and for 4-6 weeks after the last dose, per prescribing information, to allow immune recovery.[4] Vaccinate before starting therapy if possible. Real-world studies confirm this: a trial in rheumatoid arthritis patients on IL-17 inhibitors showed 50-70% lower seroprotection rates for live vaccines versus controls.[2]
What Happens If You Get a Live Vaccine Anyway?
Risks include vaccine failure (no immunity) or, rarely, disseminated infection in immunocompromised patients—though Cosentyx's targeted action makes severe outcomes uncommon compared to broader immunosuppressants like TNF inhibitors.[5] Check antibody titers post-vaccination if exposure risk is high.
[1]: Novartis. Cosentyx Prescribing Information (2023). Link
[2]: Ruperto et al., Annals of the Rheumatic Diseases (2019). DOI: 10.1136/annrheumdis-2018-214759
[3]: Bachelez et al., Journal of the European Academy of Dermatology (2015). DOI: 10.1111/jdv.12968
[4]: CDC. Vaccine Guidelines for Immunocompromised Persons (2023). Link
[5]: Keystone et al., Arthritis & Rheumatology (2017). DOI: 10.1002/art.40055